ISH | Jotup

Krispy Kreme® Announces Expansion into Germany

Retrieved on:

Wednesday, May 1, 2024

Retail, Restaurant, Bar, Convenience Store, Food, Beverage, ISH, Krispy Kreme, KFC, News, Pizza Hut, Fast food

Krispy Kreme, Inc. (NASDAQ: DNUT) today announced an agreement with restaurant group ISH Kreme to bring one of the world’s most loved sweet treats to Germany.

Key Points:

Krispy Kreme, Inc. (NASDAQ: DNUT) today announced an agreement with restaurant group ISH Kreme to bring one of the world’s most loved sweet treats to Germany.
Krispy Kreme® will offer its iconic, fresh doughnuts to German consumers through a network of Krispy Kreme shops starting in Berlin.
“We are excited to expand into Germany as it has been a priority market for us, offering substantial growth with more than 3,000 points of access,” said Raphael Duvivier, Krispy Kreme Chief Development Officer.
Each Krispy Kreme doughnut is made fresh daily, hand-crafted, and hand-decorated to ensure the melt-in-your-mouth taste that has become synonymous with the brand.

BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS

Retrieved on:

Tuesday, April 23, 2024

ISH, Trial, Investment, Research, Bio-Techne, COMET, Unified Patent Court, Acquisition, Intellectual property, ACD

MINNEAPOLIS, April 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.

Key Points:

Bio-Techne enforces intellectual property for gold standard RNAscope® ISH technology in spatial biology research and clinical applications.
RNAscope is the most referenced technology in the industry, with its rapidly growing portfolio of peer-reviewed publications recently surpassing 10,000.
In its lawsuit filed in the Unified Patent Court (a pan-European forum for resolving patent disputes), in the Netherlands Local Division of the Court of First Instance in The Hague, Bio-Techne alleges that Molecular Instruments' HCR 3.0 technology infringes ACD's European Patents 1,910,572 and 2,500,439.
The lawsuit seeks damages and injunctive relief requiring Molecular Instruments to stop infringing ACD's patents in key European markets.

BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS

Retrieved on:

Wednesday, April 10, 2024

ISH, FDA, Nature, Social media, ELISA, Cytokine, Gene editing, Conference, Research, Workflow, Diagnosis, CDT, Antibody, ACD, Drug discovery

The replay will be available from 11:00 a.m. CDT on Wednesday, May 1, 2024, until 11:00 p.m. CDT on Saturday, June 1, 2024.

Key Points:

The replay will be available from 11:00 a.m. CDT on Wednesday, May 1, 2024, until 11:00 p.m. CDT on Saturday, June 1, 2024.
These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.
With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide.
For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook , LinkedIn , Twitter or YouTube .

YR Media’s Adult ISH Podcast Season 11 Spotlights Young Leaders “Standing Up”

Retrieved on:

Thursday, April 4, 2024

Oakland, California, April 04, 2024 (GLOBE NEWSWIRE) -- Adult ISH , the award-winning advice, culture, and storytelling podcast from YR Media and part of the Radiotopia podcast network from PRX, is launching its 11th season with the first of ten episodes dropping Thursday, April 11, 2024.

Key Points:

Oakland, California, April 04, 2024 (GLOBE NEWSWIRE) -- Adult ISH , the award-winning advice, culture, and storytelling podcast from YR Media and part of the Radiotopia podcast network from PRX, is launching its 11th season with the first of ten episodes dropping Thursday, April 11, 2024.
What differences are there as a teen versus when you’re a legal adult?
“Season 11 is about young people being authentically themselves as they follow their passions.”
“As YR Media celebrates 30 years of impact – producing audio with aspiring teen and young adult podcasters, journalists, and musicians – I’m excited that Adult ISH will amplify even more of our YR Media students’ voices in this season,” said YR Media CEO Kyra Kyles.
Learn more about the podcast here and follow along on social media:

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report 2024-2030: Growing Prevalence of Target Diseases & Increasing External Funding for R&D Fueling Expansion - ResearchAndMarkets.com

Retrieved on:

Tuesday, March 26, 2024

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.

Key Points:

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.
Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.
In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth.
An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market.

BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS

Retrieved on:

Monday, April 1, 2024

ISH, Protein Sciences, Education, CiteAb, ELISA, RNA, Antibody, Research, Diagnosis, ACD, Literature, Elisa's

Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.

Key Points:

Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.
The ELISA Kit Supplier of the Year award is a testament to the depth and breadth of the R&D Systems citation database, which covers reagent data for nearly one million ELISA kit products.
CiteAb's Innovation Award recognizes ACD's RNAscope HiPlex12 Flex Kit, which provides greater flexibility to researchers performing in situ spatial detection of target RNA.
The Innovation Award given to our ACD brand underscores our Spatial Biology team's dedication to enriching our customers' experiences and prioritizing researchers' needs."

Enhanced Multiplex IHC Technology for Precision Oncology, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Tuesday, February 6, 2024

TME, Tumor microenvironment, Biomarker, Doctor of Philosophy, In situ hybridization, Drug development, Complex, RNA, Protein, ISH, Medical imaging

TORONTO, Feb. 6, 2024 /PRNewswire-PRWeb/ -- Unlock the potential of cutting-edge technology in oncology research. Dive into the latest breakthroughs in multiplex immunohistochemistry (IHC) during this upcoming webinar about Veracyte's Brightplex® technology, a prominent example of multiplex IHC advancements. This webinar will explore innovative features that elevate the capabilities of this technology, providing a deeper understanding of not only the tumor microenvironment (TME) but also the critical imperative for biomarkers in the context of clinical trials.

Key Points:

In this free webinar, learn the latest advancements surrounding Veracyte's multiplex immunohistochemistry (IHC) assay.
Attendees will discover how coupling IHC and in situ hybridization (ISH) can help in cancer research and drug development.
Dive into the latest breakthroughs in multiplex immunohistochemistry (IHC) during this upcoming webinar about Veracyte 's Brightplex® technology, a prominent example of multiplex IHC advancements.
Brightplex new features incorporate in situ hybridization (ISH) probes for the detection of RNA transcripts alongside traditional multiplex IHC biomarkers.

EQS-News: Mutares positions newly formed HILO Group as system supplier of high-quality automotive technology

Retrieved on:

Tuesday, January 30, 2024

ISH, HQ, Frankfurt Stock Exchange, Regulated market, Supervisory board, Mobility, Automotive industry, SDAX, MUX, Original equipment manufacturer, EUR, KICO, High, Growth, Fine chemical

Munich, January 25, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) is announcing the formation of another globally active automotive supplier operating under the name HILO Group.

Key Points:

Munich, January 25, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) is announcing the formation of another globally active automotive supplier operating under the name HILO Group.
The newly founded holding company will consolidate Mutares' business for innovative precision components for OEMs, including hinges and locking systems.
HILO Group, as a leading global supplier of hinge and locking systems, within the Mutares Automotive & Mobility segment, will have a significant role in its future growth development.
Robin Laik, CEO of Mutares, comments: "I am very pleased to announce the formation of HILO Group as another globally active supplier for OEMs strengthening our Automotive & Mobility segment.

Molecular Diagnostics in Oncology, Genetic/Inherited Diseases and NIPT 2023-2028 - ResearchAndMarkets.com

Retrieved on:

Monday, January 29, 2024

The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.
In addition, the fields of rare inherited/ genetic diseases and NIPT have become areas of new breakthroughs in healthcare.
These and other technologies and applications in oncology, rare inherited/ genetic disease, and NIPT molecular diagnostic testing are covered in the report.
The report contains detailed market data on the following IVD segments for their use in molecular testing:
Molecular Diagnostics in Oncology Market by Segment, 2023-2028

BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2024, TO ANNOUNCE SECOND QUARTER FISCAL 2024 FINANCIAL RESULTS

Retrieved on:

Tuesday, January 16, 2024

ISH, Research, Cytokine, ELISA, Diagnosis, Workflow, Drug discovery, CST, Conference, Antibody, FDA, Nature, ACD, Gene editing

The replay will be available from 11:00 a.m. CST on Thursday, February 1, 2024, until 11:00 p.m. CST on Friday, March 1, 2024.

Key Points:

The replay will be available from 11:00 a.m. CST on Thursday, February 1, 2024, until 11:00 p.m. CST on Friday, March 1, 2024.
Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow.
These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.
With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide.